Mark S. Freedman

Defining the clinical course of multiple sclerosis

Fred Lublin, Stephen C. Reingold, Jeffrey A. Cohen et al. · Neurology · 2014 · 3.1K citations · Full text

Medicine, Neurology, Pathology +17

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes

Ludwig Kappos, C. H. Polman, Mark S. Freedman et al. · Neurology · 2006 · 677 citations

Life Sciences, Neurology, Pharmacotherapy +12

Vitamin D as an Early Predictor of Multiple Sclerosis Activity and Progression

Alberto Ascherio, Kassandra L. Munger, Rick White et al. · JAMA Neurology · 2014 · 512 citations

Medicine, Neurology, Pharmacotherapy +17

Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study

Ludwig Kappos, Mark S. Freedman, Chris H. Polman et al. · The Lancet · 2007 · 501 citations

Life Sciences, Neurology, Neuroimmunology +9

Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial

Fred Lublin, David H. Miller, Mark S. Freedman et al. · The Lancet · 2016 · 449 citations · Full text

Medicine, Neurology, Pharmacotherapy +10